Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Saved in:
| Title: | Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103). |
|---|---|
| Authors: | Garralda E; Early Drug Development Unit, Vall d'Hebron, Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea., Italiano A; Early Phase Trials Unit, Institut Bergonié, Bordeaux, and Faculty of Medicine, University of Bordeaux, Bordeaux, France., Bedard PL; Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology & Hematology, University of Toronto, Toronto, Ontario, Canada., Delord JP; Medical Oncology Department, IUCT Oncopole, Institut Claudius Regaud, Toulouse, France., Calvo E; Centro Integral Oncológico Clara Campal, START Madrid - Clara Campal Comprehensive Cancer Center (CIOCC), Madrid, Spain., LoRusso P; Yale Cancer Center, New Haven, CT, USA., Wainberg Z; University of California Los Angeles, Los Angeles, CA, USA., Cervantes A; Department of Medical Oncology, Hospital Clínico, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Rodriguez-Vida A; Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Shemesh CS; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA., Sane R; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA., Mendus D; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA., Ding H; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA., Hendricks R; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA., Meng R; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA., Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Wu B; Early Drug Development Unit, Vall d'Hebron, Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea. |
| Source: | Journal of clinical pharmacology [J Clin Pharmacol] 2024 May; Vol. 64 (5), pp. 544-554. Date of Electronic Publication: 2024 Jan 17. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-4604 |
|---|---|
| DOI: | 10.1002/jcph.2397 |
